Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 73

1.

Hepatotoxicity with thiazolidinediones: is it a class effect?

Scheen AJ.

Drug Saf. 2001;24(12):873-88. Review.

PMID:
11735645
2.

Thiazolidinediones and liver toxicity.

Scheen AJ.

Diabetes Metab. 2001 Jun;27(3):305-13. Review.

3.

Thiazolidinedione hepatotoxicity: a class effect?

Tolman KG.

Int J Clin Pract Suppl. 2000 Oct;(113):29-34. Review.

PMID:
11965828
4.
5.

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus.

Wagstaff AJ, Goa KL.

Drugs. 2002;62(12):1805-37. Review.

PMID:
12149047
6.

Troglitazone: a review of its use in the management of type 2 diabetes mellitus.

Plosker GL, Faulds D.

Drugs. 1999 Mar;57(3):409-38. Review.

PMID:
10193691
7.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
8.

Promising new approaches.

Reasner CA 2nd.

Diabetes Obes Metab. 1999 May;1 Suppl 1:S41-8. Review.

PMID:
11220287
9.

[The development of thiazolidinedione drugs as anti-diabetic agents].

Kuzuya T.

Nihon Rinsho. 2000 Feb;58(2):364-9. Review. Japanese.

PMID:
10707559
10.

Hepatotoxicity of the thiazolidinediones.

Tolman KG, Chandramouli J.

Clin Liver Dis. 2003 May;7(2):369-79, vi. Review.

PMID:
12879989
11.

[Thiazolidinediones: clinical data and perspectives].

Blicklé JF.

Diabetes Metab. 2001 Apr;27(2 Pt 2):279-85. Review. French.

12.

Troglitazone: review and assessment of its role in the treatment of patients with impaired glucose tolerance and diabetes mellitus.

Johnson MD, Campbell LK, Campbell RK.

Ann Pharmacother. 1998 Mar;32(3):337-48. Review.

PMID:
9533065
13.

Differentiating members of the thiazolidinedione class: a focus on safety.

Lebovitz HE.

Diabetes Metab Res Rev. 2002 Mar-Apr;18 Suppl 2:S23-9. Review.

PMID:
11921435
14.

Troglitazone in type II diabetes mellitus.

Sparano N, Seaton TL.

Pharmacotherapy. 1998 May-Jun;18(3):539-48. Review.

PMID:
9620105
15.

Oral antidiabetic agents: current role in type 2 diabetes mellitus.

Krentz AJ, Bailey CJ.

Drugs. 2005;65(3):385-411. Review.

PMID:
15669880
16.

A review of rosiglitazone in type 2 diabetes mellitus.

Werner AL, Travaglini MT.

Pharmacotherapy. 2001 Sep;21(9):1082-99. Review.

PMID:
11560198
17.

Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.

Diamant M, Heine RJ.

Drugs. 2003;63(13):1373-405. Review.

PMID:
12825962
18.

Lessons from the glitazones: a story of drug development.

Gale EA.

Lancet. 2001 Jun 9;357(9271):1870-5. Review.

PMID:
11410214
19.

Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review.

Malinowski JM, Bolesta S.

Clin Ther. 2000 Oct;22(10):1151-68; discussion 1149-50. Review. Erratum in: Clin Ther. 2001 Feb;23(2):309.

PMID:
11110228
20.

The thiazolidinediones or "glitazones" a treatment option for type 2 diabetes mellitus.

Brown MN.

Med Health R I. 2000 Apr;83(4):118-20. Review.

PMID:
10821014
Items per page

Supplemental Content

Write to the Help Desk